Vaccinia virus A35R inhibits MHC class II antigen presentation

Virology

Volumn 397, Issue 1, 2010, Pages 176-186

  Rehm, Kristina E ^a   Connor, Ramsey F ^a   Jones, Gwendolyn J B ^a   Yimbu, Kenneth ^a   Roper, Rachel L ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Antigen presentation; Apoptosis; Cytokine; Macrophage; MHC; Poxvirus; Vaccinia

Indexed keywords

CHEMOKINE; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CELL ISOLATION; CELLULAR IMMUNITY; CONTROLLED STUDY; ENDOSOME; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE MICROSCOPY; NONHUMAN; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; VACCINIA VIRUS; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; ANTIGEN PRESENTATION; ENDOSOMES; HISTOCOMPATIBILITY ANTIGENS CLASS II; RATS; T-LYMPHOCYTES; VACCINIA VIRUS; VIRAL PROTEINS; VIRULENCE FACTORS;

MAMMALIA; POXVIRIDAE; VACCINIA VIRUS;

EID: 74149090031     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2009.11.008     Document Type: Article

References (59)

1. Arness M.K., Eckart R.E., Love S.S., Atwood J.E., Wells T.S., Engler R.J., Collins L.C., Ludwig S.L., Riddle J.R., Grabenstein J.D., and Tornberg D.N. Myopericarditis following smallpox vaccination. Am. J. Epidemiol. 160 7 (2004) 642-651
2. Bellows C.F., Garry R.F., and Jaffe B.M. Vaccinia virus-induced inhibition of nitric oxide production. J. Surg. Res. 111 1 (2003) 127-135
3. Broder C.C., Kennedy P.E., Michaels F., and Berger E.A. Expression of foreign genes in cultured human primary macrophages using recombinant Vaccinia virus vectors. Gene 142 (1994) 167-174
4. Campos-Neto A., Ovendale P., Bement T., Koppi T.A., Fanslow W.C., Rossi M.A., and Alderson M.R. CD40 ligand is not essential for the development of cell-mediated immunity and resistance to Mycobacterium tuberculosis. J. Immunol. 160 5 (1998) 2037-2041
5. Casey C.G., Iskander J.K., Roper M.H., Mast E.E., Wen X.J., Torok T.J., Chapman L.E., Swerdlow D.L., Morgan J., Heffelfinger J.D., Vitek C., Reef S.E., Hasbrouck L.M., Damon I., Neff L., Vellozzi C., McCauley M., Strikas R.A., and Mootrey G. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294 21 (2005) 2734-2743
6. Chahroudi A., Chavan R., Koyzr N., Waller E.K., Silvestri G., and Feinberg M.B. Vaccinia virus tropism for primary hematolymphoid cells is determined by restricted expression of a unique virus receptor. J. Virol. 79 16 (2005) 10397-10407
7. Chavrier P., Parton R.G., Hauri H.P., Simons K., and Zerial M. Localization of low molecular weight GTP binding proteins to exocytic and endocytic compartments. Cell 62 2 (1990) 317-329
8. Chen N., Li G., Liszewski M.K., Atkinson J.P., Jahrling P.B., Feng Z., Schriewer J., Buck C., Wang C., Lefkowitz E.J., Esposito J.J., Harms T., Damon I.K., Roper R.L., Upton C., and Buller R.M. Virulence differences between monkeypox virus isolates from West Africa and the Congo basin. Virology 340 1 (2005) 46-63
9. Damaso C.R., Esposito J.J., Condit R.C., and Moussatche N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 277 2 (2000) 439-449
10. Deng L., Dai P., Ding W., Granstein R.D., and Shuman S. Vaccinia virus infection attenuates innate immune responses and antigen presentation by epidermal dendritic cells. J. Virol. 80 20 (2006) 9977-9987
11. Dhar A.D., Werchniak A.E., Li Y., Brennick J.B., Goldsmith C.S., Kline R., Damon I., and Klaus S.N. Tanapox infection in a college student. N. Engl. J. Med. 350 4 (2004) 361-366
12. Dunachie S.J., Walther M., Epstein J.E., Keating S., Berthoud T., Andrews L., Andersen R.F., Bejon P., Goonetilleke N., Poulton I., Webster D.P., Butcher G., Watkins K., Sinden R.E., Levine G.L., Richie T.L., Schneider J., Kaslow D., Gilbert S.C., Carucci D.J., and Hill A.V. A DNA prime-modified Vaccinia virus ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infect. Immun. 74 10 (2006) 5933-5942
13. Eckart R.E., Love S.S., Atwood J.E., Arness M.K., Cassimatis D.C., Campbell C.L., Boyd S.Y., Murphy J.G., Swerdlow D.L., Collins L.C., Riddle J.R., Tornberg D.N., Grabenstein J.D., and Engler R.J. Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination. J. Am. Coll. Cardiol. 44 1 (2004) 201-205
14. Engelmayer J., Larsson M., Subklewe M., Chahroudi A., Cox W.I., Steinman R.M., and Bhardwaj N. Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J. Immunol. 163 12 (1999) 6762-6768
15. Fang M., and Sigal L.J. Direct CD28 costimulation is required for CD8+ T cell-mediated resistance to an acute viral disease in a natural host. J. Immunol. 177 11 (2006) 8027-8036
16. Feng Y., Press B., and Wandinger-Ness A. Rab 7: an important regulator of late endocytic membrane traffic. J. Cell Biol. 131 6 Pt. 1 (1995) 1435-1452
17. Gardella S., Andrei C., Poggi A., Zocchi M.R., and Rubartelli A. Control of interleukin-18 secretion by dendritic cells: role of calcium influxes. FEBS Lett. 481 3 (2000) 245-248
18. Humlova Z., Vokurka M., Esteban M., and Melkova Z. Vaccinia virus induces apoptosis of infected macrophages. J. Gen. Virol. 83 Pt. 11 (2002) 2821-2832
19. Inaba K., Turley S., Iyoda T., Yamaide F., Shimoyama S., Reis e Sousa C., Germain R.N., Mellman I., and Steinman R.M. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. 191 6 (2000) 927-936
20. Itano A.A., McSorley S.J., Reinhardt R.L., Ehst B.D., Ingulli E., Rudensky A.Y., and Jenkins M.K. Distinct dendritic cell populations sequentially present antigen to CD4 T cells and stimulate different aspects of cell-mediated immunity. Immunity 19 1 (2003) 47-57
21. Jenne L., Hauser C., Arrighi J.F., Saurat J.H., and Hugin A.W. Poxvirus as a vector to transduce human dendritic cells for immunotherapy: abortive infection but reduced APC function. Gene Ther. 7 18 (2000) 1575-1583
22. Karupiah G., Xie Q.W., Buller R.M.L., Nathan C., Duarte C., and Macmicking J.D. Inhibition of viral replication by interferon-gamma induced nitric oxide synthase. Science 261 (1993) 1445-1448
23. Kastenmuller W., Drexler I., Ludwig H., Erfle V., Peschel C., Bernhard H., and Sutter G. Infection of human dendritic cells with recombinant Vaccinia virus MVA reveals general persistence of viral early transcription but distinct maturation-dependent cytopathogenicity. Virology 350 2 (2006) 276-288
24. Kolhapure R.M., Deolankar R.P., Tupe C.D., Raut C.G., Basu A., Dama B.M., Pawar S.D., Joshi M.V., Padbidri V.S., Goverdhan M.K., and Banerjee K. Investigation of buffalopox outbreaks in Maharashtra State during 1992-1996. Indian J. Med. Res. 106 (1997) 441-446
25. Lee M.S., Roos M., McGuigan L.C., Smith K.A., Cormier N., Cohen L.K., Roberts B.E., and Payne L.G. Molecular attenuation of Vaccinia virus: mutant generation and animal characterization. J.Virol 66 (1992) 2617-2630
26. Lederman E., Miramontes R., Openshaw J., Olson V.A., Karem K.L., Marcinak J., Panares R., Staggs W., Allen D., Weber S.G., Vora S., Gerber S.I., Hughes C.M., Regnery R., Collins L., Diaz P.S., Reynolds M.G., and Damon I. Eczema vaccinatum resulting from the transmission of Vaccinia virus from a smallpox vaccinee: an investigation of potential fomites in the home environment. Vaccine 27 3 (2009) 375-377
27. Li P., Wang N., Zhou D., Yee C.S., Chang C.H., Brutkiewicz R.R., and Blum J.S. Disruption of MHC class II-restricted antigen presentation by Vaccinia virus. J. Immunol. 175 10 (2005) 6481-6488
28. Lippincott-Schwartz J., and Fambrough D.M. Cycling of the integral membrane glycoprotein, LEP100, between plasma membrane and lysosomes: kinetic and morphological analysis. Cell 49 5 (1987) 669-677
29. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu. Rev. Immunol. 15 (1997) 323-350
30. Mahalingam S., Damon I.K., and Lidbury B.A. 25 years since the eradication of smallpox: why poxvirus research is still relevant. Trends Immunol. 25 12 (2004) 636-639
31. Mann B.A., Huang J.H., Li P., Chang H.C., Slee R.B., O'Sullivan A., Anita M., Yeh N., Klemsz M.J., Brutkiewicz R.R., Blum J.S., and Kaplan M.H. Vaccinia virus blocks Stat1-dependent and Stat1-independent gene expression induced by type I and type II interferons. J. Interferon Cytokine Res. 28 6 (2008) 367-380
32. Mannie M.D., and Norris M.S. MHC class-II-restricted antigen presentation by myelin basic protein-specific CD4+ T cells causes prolonged desensitization and outgrowth of CD4- responders. Cell Immunol. 212 1 (2001) 51-62
33. Martina B.E., van Doornum G., Dorrestein G.M., Niesters H.G., Stittelaar K.J., Wolters M.A., van Bolhuis H.G., and Osterhaus A.D. Cowpox virus transmission from rats to monkeys, the Netherlands. Emerg. Infect. Dis. 12 6 (2006) 1005-1007
34. Matz-Rensing K., Ellerbrok H., Ehlers B., Pauli G., Floto A., Alex M., Czerny C.P., and Kaup F.J. Fatal poxvirus outbreak in a colony of New World monkeys. Vet Pathol 43 2 (2006) 212-218
35. Molino A.C., Fleischer Jr. A.B., and Feldman S.R. Patient demographics and utilization of health care services for molluscum contagiosum. Pediatr. Dermatol. 21 6 (2004) 628-632
36. Moss B. Poxviruses. In: Knipe D.M., and Howley P.M. (Eds). Fields Virology Vol. 2 (2001), Lippincott Williams & Wilkins, Philadelphia 2849-2884
37. Reading P.C., and Smith G.L. Vaccinia virus interleukin-18-binding protein promotes virulence by reducing gamma interferon production and natural killer and T-cell activity. J. Virol. 77 18 (2003) 9960-9968
38. Rehm K.E., Connor R.F., Jones G.J.B., Yimbu K., Mannie M.D., and Roper R.L. Vaccinia virus decreases MHC class II antigen presentation, T cell priming, and peptide association with MHC class II. Immunology 128 (2009) 381-392
39. Rehm K.E., Jones G.J.B., Tripp A.A., Metcalf M.W., and Roper R.L. The Poxvirus A35 Protein is an Immunoregulator. J. Virol. 84 (2010) 176-186
40. Robertson D., Paterson H.F., Adamson P., Hall A., and Monaghan P. Ultrastructural localization of ras-related proteins using epitope-tagged plasmids. J. Histochem. Cytochem. 43 5 (1995) 471-480
41. Roper R.L. Characterization of the Vaccinia virus A35R protein and its role in virulence. J. Virol. 80 1 (2006) 306-313
42. Rudensky A., Rath S., Preston-Hurlburt P., Murphy D.B., and Janeway Jr. C.A. On the complexity of self. Nature 353 6345 (1991) 660-662
43. Sanchez-Puig J.M., Sanchez L., Roy G., and Blasco R. Susceptibility of different leukocyte cell types to Vaccinia virus infection. Virol. J. 1 1 (2004) 10
44. Schell J., Rose N.F., Fazo N., Marx P.A., Hunter M., Ramsburg E., Montefiori D., Earl P., Moss B., and Rose J.K. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 27 7 (2009) 979-986
45. Smee D.F., and Sidwell R.W. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids 23 1-2 (2004) 375-383
46. Stack J., Haga I.R., Schroder M., Bartlett N.W., Maloney G., Reading P.C., Fitzgerald K.A., Smith G.L., and Bowie A.G. Vaccinia virus protein A46R targets multiple Toll-like-interleukin-1 receptor adaptors and contributes to virulence. J. Exp. Med. 201 6 (2005) 1007-1018
47. Steinborn A., Essbauer S., and Marsch W. [Human cowpox/catpox infection. A potentially unrecognized disease]. Dtsch. Med. Wochenschr. 128 12 (2003) 607-610
48. Stich A., Meyer H., Kohler B., and Fleischer K. Tanapox: first report in a European traveller and identification by PCR. Trans. R. Soc. Trop. Med. Hyg. 96 2 (2002) 178-179
49. Stimpfling J.H., and Richardson A. Recombination within the histocompatibility-2 locus of the mouse. Genetics 51 (1965) 831-846
50. Stober C.B., Lange U.G., Roberts M.T., Alcami A., and Blackwell J.M. Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB/c Mice. Infect. Immun. 75 2 (2007) 852-860
51. Upfal M.J., and Cinti S. Smallpox vaccination and adverse cardiac events. Emerg. Infect. Dis. 10 (5 (2004) 961-962 discussion 962
52. Upton C., Slack S., Hunter A.L., Ehlers A., and Roper R.L. Poxvirus orthologous cluster: toward defining the minimum essential poxvirus genome. J. Virol. 77 (2003) 7590-7600
53. Upton C., Slack S., Hunter A.L., Ehlers A., and Roper R.L. Poxvirus orthologous clusters: toward defining the minimum essential poxvirus genome. J. Virol. 77 13 (2003) 7590-7600
54. Vijaysri S., Jentarra G., Heck M.C., Mercer A.A., McInnes C.J., and Jacobs B.L. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 26 5 (2008) 664-676
55. Viner K.M., Girgis N., Kwak H., and Isaacs S.N. B5-deficient Vaccinia virus as a vaccine vector for the expression of a foreign antigen in Vaccinia immune animals. Virology (2006)
56. Webb T.J., Litavecz R.A., Khan M.A., Du W., Gervay-Hague J., Renukaradhya G.J., and Brutkiewicz R.R. Inhibition of CD1d1-mediated antigen presentation by the Vaccinia virus B1R and H5R molecules. Eur. J. Immunol. 36 10 (2006) 2595-2600
57. Wyatt L.S., Earl P.L., Eller L.A., and Moss B. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic Vaccinia virus challenge. Proc. Natl. Acad. Sci. U. S. A. 101 13 (2004) 4590-4595
58. Xu R., Johnson A.J., Liggitt D., and Bevan M.J. Cellular and humoral immunity against Vaccinia virus infection of mice. J. Immunol. 172 10 (2004) 6265-6271
59. Yao Y., Li P., Singh P., Thiele A.T., Wilkes D.S., Renukaradhya G.J., Brutkiewicz R.R., Travers J.B., Luker G.D., Hong S.C., Blum J.S., and Chang C.H. Vaccinia virus infection induces dendritic cell maturation but inhibits antigen presentation by MHC class II. Cell Immunol. 246 2 (2007) 92-102